

Vlatko Pejša

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7035146/publications.pdf>

Version: 2024-02-01

35
papers

1,635
citations

1163117

8
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

1941
citing authors

#	ARTICLE	IF	CITATIONS
1	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	27.0	1,407
2	CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. <i>Blood</i> , 2004, 103, 1968-1969.	1.4	49
3	The Degree of Anisocytosis Predicts Survival in Patients with Primary Myelofibrosis. <i>Acta Haematologica</i> , 2016, 136, 98-100.	1.4	16
4	Elevated Neutrophil-to-Lymphocyte-ratio and Platelet-to-Lymphocyte Ratio in Myelofibrosis: Inflammatory Biomarkers or Representatives of Myeloproliferation Itself?. <i>Anticancer Research</i> , 2018, 38, 3157-3163.	1.1	16
5	The accuracy of fine needle aspiration cytology and flow cytometry in evaluation of nodal and extranodal sites in patients with suspicion of lymphoma. <i>Collegium Antropologicum</i> , 2010, 34, 131-7.	0.2	15
6	Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. <i>Croatian Medical Journal</i> , 2017, 58, 40-48.	0.7	12
7	Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires. <i>Radiology and Oncology</i> , 2019, 53, 337-347.	1.7	11
8	Canonical Wnt/ β -Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 523-526.	0.4	9
9	Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2019, 98, 1509-1510.	1.8	9
10	Ruxolitinib treatment improves muscle mass in patients with myelofibrosis. <i>Annals of Hematology</i> , 2021, 100, 1105-1106.	1.8	9
11	Heat shock protein 27 (HSP27/HSPB1) expression is increased in patients with primary and secondary myelofibrosis and may be affecting their survival. <i>Leukemia and Lymphoma</i> , 2017, 58, 2497-2500.	1.3	8
12	Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis. <i>International Journal of Hematology</i> , 2018, 107, 166-172.	1.6	8
13	Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. <i>Krohem B-CII 2017. Acta Clinica Croatica</i> , 2018, 57, 190-215.	0.2	8
14	Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears. <i>Collegium Antropologicum</i> , 2010, 34, 425-9.	0.2	8
15	Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. <i>Leukemia Research</i> , 2018, 66, 89-95.	0.8	6
16	Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality. <i>American Journal of Hematology</i> , 2019, 94, E42-E43.	4.1	5
17	Combining information on C reactive protein and serum albumin into the Glasgow Prognostic Score strongly discriminates survival of myelofibrosis patients. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 14-16.	1.4	4
18	Perirenal and subcutaneous fat differently affect outcomes in newly diagnosed classical Hodgkin lymphoma patients. <i>Hematological Oncology</i> , 2021, 39, 575-579.	1.7	4

#	ARTICLE	IF	CITATIONS
19	More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 1037-1044.	2.0	4
20	No adverse effect of ABVD chemotherapy in a patient with chronic hepatitis C and Hodgkin's disease. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 695-697.	1.9	3
21	Multicentric glial brain tumors of a varying degree of differentiation in patient with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2005, 79, 50-53.	4.1	3
22	Myelomatous ascites in patient with liver cirrhosis: A case report. <i>Diagnostic Cytopathology</i> , 2009, 37, 780-782.	1.0	3
23	Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 934-939.	1.3	3
24	Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type. <i>Leukemia and Lymphoma</i> , 2021, 62, 2535-2538.	1.3	3
25	Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes. <i>Leukemia and Lymphoma</i> , 2022, 63, 1556-1565.	1.3	3
26	Rapid decrease in high titer of factor VIII inhibitors upon immunosuppressive treatment in severe postpartum acquired hemophilia A. <i>Croatian Medical Journal</i> , 2004, 45, 213-6.	0.7	3
27	Pulmonary Blastoma with Fatal Hypercalcemia. <i>Respiration</i> , 1997, 64, 247-250.	2.6	2
28	Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia. <i>Annals of Hematology</i> , 2015, 94, 1617-1619.	1.8	1
29	Reactive macrophage activation syndrome in a patient with parvovirus B19 infection, lymphocytic lichenoid vasculitis, urticaria and angioedema. <i>Annals of Saudi Medicine</i> , 2010, 30, 88-89.	1.1	1
30	Diffuse skin hyperpigmentation in CD30+ lymphoproliferation. <i>Annals of Saudi Medicine</i> , 2012, 32, 318-320.	1.1	1
31	Bone marrow and peripheral blood hematopoietic reserve in patients with B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2003, 88, 1429-31.	3.5	1
32	Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis. <i>Annals of Hematology</i> , 2018, 97, 1293-1294.	1.8	0
33	GLI-1, Effector of Canonical Hedgehog Signaling Pathway, Might not be Dysregulated and has a Neutral Effect on Survival in Patients with Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S347-S348.	0.4	0
34	Different Pattern of CD154 and CD40 Expression On B-CLL and T Lymphocytes In Peripheral Blood, Bone Marrow and Lymph Node Microenvironment In B-Cell Chronic Lymphocytic Leukemia (B-CLL). <i>Blood</i> , 2010, 116, 3607-3607.	1.4	0
35	Different Pattern of Expression of CD52, CD20 and CXCR-4 in Peripheral Blood, Bone Marrow and Lymph Nodes in B-Cell Chronic Lymphocytic Leukemia (B-CLL). <i>Blood</i> , 2011, 118, 3877-3877.	1.4	0